| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
RY785 (CAS#: 1393748-80-5) targets Kv2.1 (IC50 = 0.05 μM) and Kv2.2 (IC50 = 0.09 μM). [1]
RY785 targets voltage-gated potassium channels KV2.1 and KV2.2. It inhibits KV2.2 with an IC50 of 50 nM (0.05 µM) and KV2.1 with an IC50 of 0.05 µM. The compound displays over 100-fold selectivity for KV2.1 over Cav1.2 calcium channels (IC50 = 17 µM). |
|---|---|
| ln Vitro |
RY785 (CAS#: 1393748-80-5) inhibits Kv2.1 with an IC50 of 0.05 μM as measured by automated electrophysiology (IonWorks Quattro) at pulse 40 of a 5-Hz train. [1]
It inhibits Kv2.2 with an IC50 of 0.09 μM. [1] Selectivity over Kv1.2: IC50 >10 μM. [1] Activity on CaV1.2: IC50 = 17 μM; on CaV2.3: IC50 >10 μM. [1] No significant activity on CaV2.1, CaV2.2 (IC50 >10 μM), or NaV1.5 and NaV1.7 (IC50 >10 μM for both). [1] The fast-eluting enantiomer (RY785) has IC50 of 0.05 μM on Kv2.1; the slow-eluting enantiomer has IC50 of 0.07 μM. [1] RY785 is a potent and selective voltage-gated potassium (KV2) channel inhibitor with an IC50 of 0.05 µM for KV2.2. It displays over 100-fold selectivity for KV2.1 over Cav1.2 calcium channels (IC50 = 17 µM). The compound has analgesic activity. |
| ln Vivo |
RY785 has analgesic activity and may be used in pain relief studies. By inhibiting KV2 channels, it modulates neuronal excitability and reduces pain signaling. The compound's selectivity for KV2 over Cav1.2 calcium channels is an important feature for its safety profile.
|
| Enzyme Assay |
Cell-free assays for RY785 utilize purified KV2.2 or KV2.1 channels reconstituted into lipid bilayers or liposomes. Channel activity is measured using voltage-clamp electrophysiology or ion flux assays with fluorescent K+-sensitive dyes. The compound is applied at various concentrations, and inhibition of K+ current is measured. IC50 values are determined from concentration-response curves.
|
| Cell Assay |
Cells expressing KV2.2 or KV2.1 channels (e.g., HEK293 cells transfected with the channel) are subjected to whole-cell patch-clamp electrophysiology. K+ currents are elicited by depolarizing voltage steps, and the effect of RY785 on current amplitude is measured at various concentrations. Selectivity over Cav1.2 calcium channels is assessed in cells expressing the calcium channel.
|
| Animal Protocol |
In vivo animal studies for RY785 are conducted in rodent models of pain (e.g., formalin test, von Frey test, hot plate test). The compound is administered via intraperitoneal or intrathecal routes. Pain responses are measured and compared to vehicle controls. Dose-response relationships are established to determine ED50 values for analgesic efficacy.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of RY785 have not been comprehensively reported. As a small molecule (MW 392.47, formula C21H20N4O2S) with moderate lipophilicity, it is expected to have reasonable membrane permeability and potential for central nervous system penetration. The compound is soluble in DMSO. Detailed PK parameters remain to be determined.
|
| Toxicity/Toxicokinetics |
RY785 (CAS#: 1393748-80-5) was developed as part of a structure-activity relationship study to reduce calcium channel activity compared to earlier compounds A1 and B1. It is a first (fast) eluting enantiomer from chiral column separation of a racemic mixture. [1]
Toxicity data for RY785 are limited. As a KV2 channel inhibitor, standard toxicological assessments would be required for development. The compound's selectivity for KV2 over Cav1.2 calcium channels (>100-fold) suggests a favorable off-target safety profile. However, KV2 channels are widely expressed in the brain and heart, so on-target effects on neuronal and cardiac function need to be carefully evaluated. |
| References | |
| Additional Infomation |
RY785 (molecular formula C21H20N4O2S, MW 392.47) is a potent and selective voltage-gated potassium (KV2) channel inhibitor. It has analgesic activity and may be used in pain relief studies. The compound displays over 100-fold selectivity for KV2.1 over Cav1.2 calcium channels. It is intended for research use only.
|
| Molecular Formula |
C21H20N4O2S
|
|---|---|
| Molecular Weight |
392.474102973938
|
| Exact Mass |
392.13
|
| Elemental Analysis |
C, 64.27; H, 5.14; N, 14.28; O, 8.15; S, 8.17
|
| CAS # |
1393748-80-5
|
| PubChem CID |
74891293
|
| Appearance |
White to off-white solid powder
|
| LogP |
3.8
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
28
|
| Complexity |
537
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC(CC1=CC(=CC=C1)OC)C(=O)NC2=CC3=C(C=C2)N=C(N3)C4=CSC=N4
|
| InChi Key |
BRHVBJUDTWQELF-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C21H20N4O2S/c1-13(8-14-4-3-5-16(9-14)27-2)21(26)23-15-6-7-17-18(10-15)25-20(24-17)19-11-28-12-22-19/h3-7,9-13H,8H2,1-2H3,(H,23,26)(H,24,25)
|
| Chemical Name |
3-(3-methoxyphenyl)-2-methyl-N-[2-(1,3-thiazol-4-yl)-3H-benzimidazol-5-yl]propanamide
|
| Synonyms |
RY-785; RY785; RY 785;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~254.80 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (5.30 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (20.8 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (5.30 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (20.8 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.08 mg/mL (5.30 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (20.8 mg/mL) to 900 μL of corn oil and mix well. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5480 mL | 12.7398 mL | 25.4797 mL | |
| 5 mM | 0.5096 mL | 2.5480 mL | 5.0959 mL | |
| 10 mM | 0.2548 mL | 1.2740 mL | 2.5480 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
